Previous close | 1.2900 |
Open | 1.2900 |
Bid | 1.1700 x 100 |
Ask | 1.2600 x 100 |
Day's range | 1.1800 - 1.3200 |
52-week range | 0.4700 - 6.7400 |
Volume | |
Avg. volume | 170,133 |
Market cap | 38.178M |
Beta (5Y monthly) | 0.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Amidst revenue decline and significant cash burn, Durect Corp reports promising clinical trial results and strategic FDA interactions.
Durect (DRRX) delivered earnings and revenue surprises of -19.05% and 33.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?